基于区域专利信息服务(南京)中心的新型冠状病毒肺炎防治技术专利情报分析研究  

Analysis on patent intelligence of COVID-19 prevention technology based on Regional Patent Information Dervice (Nanjing) Center

作　　者：周爱平[1] 张语馨 王健[1] 龚跃鹏 薛倩 王亚利 Zhou Aiping;Zhang Yuxin;Wang Jian;Gong Yuepeng;Xue Qian;Wang Yali(The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,Jiangsu Province,China;Patent Information Service Center of Jiangsu,Nanjing 210008,Jiangsu Province,China)

机构地区：[1]南京大学医学院附属鼓楼医院,210008 [2]江苏省专利信息服务中心,南京210008

出　　处：《中华医学科研管理杂志》2021年第4期284-291,共8页Chinese Journal of Medical Science Research Management

基　　金：南京市医学科技发展资金资助项目(YKK18082,QRX17145)。

摘　　要：目的本研究对全球103个国家或地区新型冠状病毒肺炎防治技术的发明专利进行分析,了解全球新型冠状病毒肺炎防治技术研发的最新研究动态,探讨研发方向,为跨学科、多团队合作提供理论依据。方法结合国家知识产权局区域专利信息服务(南京)中心检索与分析系统和IncoPat科技创新情报共同构建检索策略,以三级分支为单位,分开检索论证,检索式运用IPC分类号加关键词限定;专利类型限定为发明专利。结果截至2020年2月14日,全球新型冠状病毒肺炎防治技术发明专利共申请136087件。从申请来源国来看,美国共56095件,位居榜首,排名第二为中国共18096件。从技术领域来看,排名前3的分别是化学治疗药物(47634件)、疫苗(47248件)和诊断检测(12991件),美国在以上3个技术领域的专利布局都具有绝对优势。从专利申请人来看,国外新型冠状病毒肺炎相关技术的专利申请人主要是大型企业,中国主要是高校和科研院所。结论我国新型冠状病毒肺炎相关专利申请较为分散,在化学治疗领域与世界领先国家存在一定差距,科研院所与企业间的合作不够紧密。首先应进一步加大化学药物研发的投入,积极推动疫苗技术的研发;其次巩固已经积累的相关技术和产品优势,加强知识产权的保护和布局;最后促进产学研合作,创建技术创新体系,鼓励科技创新成果转化实施。ObjectiveThis study analyzes COVID-19 prevention and treatment technology patents from 103 countries and regions worldwide, in order to have a good grasp of the most-current trends in COVID-19 prevention and treatment technology research worldwide, discuss the research directions of such technologies, provide theoretical foundations for interdisciplinary and multi-team cooperation.MethodsThe retrieval strategies were constructed utilizing the retrieval and analysis system by the Regional Patent Information Service (Nanjing) Center of The State Intellectual Property Office and IncoPat's scientific and technological innovation platform, using third-level branches as the unit and separating the retrieval and proof processes, the queries built using IPC classification numbers and key words;the search was limited to invention patents, with utility models and designs excluded.ResultsOn February 14, 2020, there had been a total number of 136 087 invention patent applications for COVID-19 prevention and treatment technologies globally. In terms of the country of origin, the U. S. ranked first with 56 095 patents, followed by China (18 096). In terms of technical field, the top three were chemical therapeutic agents (47 634), vaccines (47 248) and diagnostic tests (12 991), with the U. S. possessing absolutely advantageous patent portfolios in all three fields. The applicants were mainly comprised of large enterprises abroad and universities and research institutes in China.ConclusionsChina′s COVID-19 related patent applications are relatively scattered. In the field of chemotherapy, there is room for improvement compared with the advanced countries, and cooperation between scientific institutions and enterprises is insufficient. Therefore, China should further increase investment in chemical drug research and development and seize the opportunity to actively promote the research and development of vaccine technology. On the other hand, we need to consolidate the technical advantages and product advantages of epidemic p

关 键 词：新型冠状病毒肺炎 发明专利 情报分析 

分 类 号：G255.53[文化科学—图书馆学] R563.1[医药卫生—呼吸系统]